Pictured: 3D image of a KRAS oncogene iStock/Gilnature

图为KRAS致癌基因iStock/Gilnature的3D图像

BridgeBio announced Thursday that it has secured $200 million in financing to spinout a former subsidiary to develop a KRAS-focused oncology portfolio.

BridgeBio周四宣布，它已获得2亿美元的融资，以推出一家前子公司，开发以KRAS为重点的肿瘤学投资组合。

Called BridgeBio Oncology Therapeutics (BBOT), the company was initially formed as a subsidiary of BridgeBio known as TheRas. According to an SEC filing, the subsidiary has existed since 2016 and formed a research and development agreement with Leidos Biomedical Research in 2017.

该公司名为BridgeBio Oncology Therapeutics（BBOT），最初是作为BridgeBio的子公司TheRas成立的。根据SEC提交的文件，该子公司自2016年成立，并于2017年与Leidos Biomedical research签订了研发协议。

BBOT’s mission now is to generate a pipeline of small molecule therapeutics targeting RAS and PI3K malignancies. The company aims to advance three programs, including BBO-8520, a direct inhibitor of KRAS that seeks to bind to the protein’s “on” and “off” states. The spinout is enrolling patients with mutant non-small cell lung cancer in a Phase Ia/Ib trial..

BBOT现在的任务是开发一系列针对RAS和PI3K恶性肿瘤的小分子治疗药物。该公司旨在推进三个项目，包括BBO-8520，一种KRAS的直接抑制剂，旨在结合蛋白质的“开”和“关”状态。该项目正在Ia/Ib期试验中招募突变型非小细胞肺癌患者。

A second asset that BBOT will be advancing is BBO-10203, a PI3Kα:RAS breaker that blocks the interaction between RAS and PI3Ka to inhibit the PI3Kα/AKT effector signaling in tumors. The company plans to file an IND application sometime in the second quarter of 2024 and enroll patients later this year..

BBOT将推进的第二项资产是BBO-10203，一种PI3Kα：RAS破坏剂，可阻断RAS和PI3Ka之间的相互作用，从而抑制肿瘤中的PI3Kα/AKT效应子信号传导。该公司计划在2024年第二季度的某个时候提交IND申请，并在今年晚些时候招收患者。

The other asset is BBO-11818, a pan-KRAS inhibitor that is going after the “on” and “off” states of KRASG12X, and BBOT plans to file an IND sometime in early 2025.

另一项资产是BBO-11818，一种泛KRAS抑制剂，正在追踪KRASG12X的“开”和“关”状态，BBOT计划在2025年初的某个时候提交IND。

The company is also pursuing a discovery-stage research program focused on developing assets that target additional oncogenic drivers within the RAS and PI3K pathways.

该公司还正在进行一项发现阶段的研究计划，重点是开发针对RAS和PI3K途径中其他致癌驱动因素的资产。

“We believe the launch of BBOT better aligns investors with an opportunity that was being hidden in our pipeline, and our partnership with these new investors enables us to prosecute these oncology programs more quickly and with higher fidelity,” BridgeBio CEO Neil Kumar said in a statement.

BridgeBio首席执行官尼尔·库马尔（NeilKumar）在一份声明中表示：“我们相信BBOT的推出可以更好地将投资者与隐藏在我们渠道中的机会联系起来，我们与这些新投资者的合作关系使我们能够更快、更忠实地开展这些肿瘤学项目。”

The spinout secured its $200 million financing in an oversubscribed round led by Cormorant Asset Management and co-led by Omega Funds. There was also participation from GV (Google Ventures), Deerfield Management, EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital, Casdin Captial, Aisling Capital, and Longwood Fund..

该分拆项目在由鸬鹚资产管理公司（Cormorant Asset Management）牵头、欧米茄基金（Omega Funds）共同牵头的一轮超额认购中获得了2亿美元的融资。GV（Google Ventures）、Deerfield Management、EcoR1 Capital、惠灵顿管理公司、Enavate Sciences、Surveyor Capital、Casdin Capital、Aisling Capital和Longwood Fund也有参与。

BBOT will headed by Eli Wallace, BridgeBio’s CEO of oncology R&D. Wallace joined BridgeBio in 2019 after serving as the chief scientific officer at Peloton Therapeutics. Kumar will also serve as a director of BBOT.

BBOT将由BridgeBio肿瘤研发首席执行官Eli Wallace领导。Wallace在担任Peloton Therapeutics首席科学官后，于2019年加入BridgeBio。库马尔还将担任BBOT的董事。

“In conjunction with BridgeBio and an amazing suite of investors, we look forward to seeing all three of our programs progress into the clinic over the next 12 months,” Wallace said in a statement.

华莱士在一份声明中说：“我们期待着与BridgeBio和一群令人惊叹的投资者一起，在未来12个月内看到我们所有三个项目在诊所取得进展。”

BridgeBio has gone down the spinout path before, launching QED Therapeutics in 2018. The company secured $65 million and aimed to develop infigratinib, a cancer asset that Novartis abandoned. Infigratinib was given accelerated approval by the FDA in 2021.

BridgeBio之前已经走上了外延式发展的道路，于2018年推出了QED Therapeutics。该公司获得了6500万美元的资金，旨在开发英夫利替尼，这是诺华放弃的一种癌症资产。Infiglatinib于2021年获得FDA加速批准。

Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

泰勒·帕肯（Tyler Patchen）是BioSpace的一名全职作家。你可以通过tyler.patchen@biospace.com.在LinkedIn上关注他。